Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease

Table 1 Biologic agents currently used or under study for the treatment of pediatric Crohn’s disease

Class	Biologics	FDA approval for CD	Pediatric CD indications
Anti-TNF	Infliximab	Adult: 1998; Pediatric: 2006	Moderate to severe diseases refractory to conventional therapy[10]
	Adalimumab	Adult: 2007; Pediatric: 2012	First-line therapy for patients with CD who are at risk for progressive disease or for whom corticosteroids may exacerbate underlying conditions[10]; Prophylactic therapy for preventing postoperative recurrence in high-risk patients[10]
Anti-α4β7 integrin	Vedolizumab	Adult: 2014; Pediatric: N/A	Guideline recommendations for this pediatric indication are not yet available
IL-12/23 p40 inhibitor	Ustekinumab	Adult: 2016; Pediatric: N/A	Second-line biologic therapy after anti-TNF agent failure[11]

FDA: Food and Drug Administration; CD: Crohn’s disease; TNF: Tumor necrosis factor; IL: Interleukin; N/A: Not applicable.